Author Declan Walsh Honored With National Leade...
PHILADELPHIA, May 7 /PRNewswire/ --
- Dr. Walsh is the Primary Editor of Palliative Medicine, a new Clinical
Reference Published by Elsevier
Elsevier, the world's leading publisher of scientific,
technical, and medical information products and services, congratulates
Declan Walsh, MSc, FACP, FRCP (Edin) on receiving the American Academy of
Hospice and Palliative Medicine's 2009 Project on Death in America (PDIA)
Palliative Medicine National Leadership Award
(http://www.aahpm.org/membership/awards.html) at the AAHPM 2009 Annual
Assembly on March 26.
This award recognizes a physician leader who has advanced the
field of palliative care by the education of the next generation of
palliative care leaders. The award program promotes the visibility and
prestige of physicians in both academic and clinical settings who are
committed to mentoring future leaders and serving as role models for other
health professionals engaged in improving the care of the dying. The award
was bestowed upon Dr. Walsh in recognition of his significant lifetime
contribution to the field of palliative medicine.
Dr. Walsh established the Palliative Medicine program at the
Cleveland Clinic in 1988 - the first such program in the United States. It
still remains one of the few fully integrated programs in the U.S., and in
1991 it was designated a national and international demonstration project by
the World Health Organization. In 1989, the first fellowship program in
Palliative Medicine in the United States was established under Dr. Walsh with
support of the Cleveland Clinic Foundation. In 1996 an endowed Chair of
Palliative Medicine was created at the Cleveland Clinic with Dr. Walsh as the
first incumbent - the first such endowed Chair in the United States. Dr.
Walsh is a founding member of both the European Association of Palliative
Care and the American Academy of Hospice and Palliative Medicine.
Dr. Walsh is also the primary editor of Palliative Medicine
(http://www.us.elsevierhealth.com/isbn/9780323040211/Palliative-Medicine), a
new clinical reference published by Elsevier that is designed to help
physicians provide effective palliative care to patients. Dr. Walsh said, "In
2008 palliative medicine was recognized for the first time as an official
specialty in the United States. It is a fast-growing, rewarding, and
challenging field, which is also developing rapidly internationally.
Practitioners in this field need specific, useful resources to treat their
patients effectively."
Notes to Editors:
Dr. Declan Walsh is available for interviews by contacting Tom
Reller at T.Reller@Elsevier.com. Palliative Medicine (ISBN: 9780323056748)
(http://www.us.elsevierhealth.com/isbn/9780323056748/Palliative-Medicine) is
1520 pages, with approximately 700 illustrations, and includes full-text
online access. The Premium Edition (ISBN: 9780323040211)
(http://www.us.elsevierhealth.com/isbn/9780323040211/Palliative-Medicine)
includes regular online updates as well as additional bonus features. Both
are available at http://www.us.elsevierhealth.com. For review copies, please
contact Helena Mutak at h.mutak@elsevier.com or at +1-215-239-3509.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical
and medical information products and services. Working in partnership with
the global science and health communities, Elsevier's 7,000 employees in over
70 offices worldwide publish more than 2,000 journals and 1,900 new books per
year, in addition to offering a suite of innovative electronic products, such
as ScienceDirect (http://www.sciencedirect.com/), MD Consult
(http://www.mdconsult.com/), Scopus (http://www.info.scopus.com/),
bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a
world-leading publisher and information provider. Operating in the science
and medical, legal, education, and business-to-business sectors, Reed
Elsevier provides high-quality and flexible information solutions to users,
with increasing emphasis on the Internet as a means of delivery. Reed
Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock
Exchange), RUK, and ENL (New York Stock Exchange).
Contact:
Tom Reller
+1-212-462-1912
T.Reller@Elsevier.com
AI Summary Disclaimer BETA
The content you are viewing has been generated or assisted by artificial
intelligence (AI). While efforts are made to ensure accuracy and clarity, AI-generated text may
contain inaccuracies, outdated information, or subjective interpretations. This content is intended
for general informational purposes only and should not be considered professional advice or factual
confirmation.
We encourage you to independently verify any information provided,
especially if it will be relied upon for making decisions or taking action. Any reliance you place
on this material is strictly at your own risk. The AI system that produced this content cannot
assess the specifics of individual circumstances, and results may vary based on context and
individual needs.
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.
Create an Account
Create your FREE account to receive personalised announcements, watchlists, market updates, investment insights and new features.
Personalise your experience
Tell us a little about yourself to receive personalised content, announcements and relevant investment opportunities.